Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
-0.73 (-8.18%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.18 - 9.06
52 week 6.13 - 25.60
Open 9.06
Vol / Avg. 0.00/805,385.00
Mkt cap 454.54M
P/E     -
Div/yield     -
EPS -1.26
Shares 51.02M
Beta     -
Inst. own 65%
Aug 4, 2015
Q2 2015 Regulus Therapeutics Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Regulus Therapeutics Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 30, 2015
Regulus Therapeutics Inc at BMO Capital Markets San Francisco Biotech Corporate Access Day Add to calendar
Jun 10, 2015
Regulus Therapeutics Inc Annual Shareholders Meeting
May 7, 2015
Q1 2015 Regulus Therapeutics Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Regulus Therapeutics Inc Earnings Release
May 6, 2015
Regulus Therapeutics Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -344.93% -739.08%
Operating margin -349.57% -743.62%
EBITD margin - -566.05%
Return on average assets -34.55% -38.49%
Return on average equity -41.68% -50.28%
Employees 85 -
CDP Score - -


Suite 210, 3545 John Hopkins Court
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Paul C. Grint M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Neil W. Gibson Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David L. Szekeres Chief Business Officer, General Counsel, Corporate Secretary
Age: 41
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 61
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Bruce L. A. Carter Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Mark G. Foletta CPA Independent Director
Age: 54
Bio & Compensation  - Reuters